From our review of cases from the TCGA and METABRIC datasets [16], about 15% of breast cancer cases show FAK-copy-gain (Figure 2D), suggesting that treatment with FAK inhibitors might be beneficial for a significant fraction of breast cancer patients. Here, PTK2 is linked to breast carcinoma.